Peginterferon alpha-2b is indicated for:
Population group: only adults (18 - 65 years old)
Peginterferon alpha-2b in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adult patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Peginterferon alpha-2b is indicated for the treatment of adult patients (18 years of age and older) with CHC who are positive for hepatitis C virus RNA (HCV-RNA), including patients with compensated cirrhosis and/or co-infected with clinically stable HIV.
Peginterferon alpha-2b in combination with ribavirin (bitherapy) is indicated for the treatment of CHC infection in adult patients who are previously untreated including patients with clinically stable HIV co-infection and in adult patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated) and ribavirin combination therapy or interferon alpha monotherapy.
Interferon monotherapy, including peginterferon alpha-2b, is indicated mainly in case of intolerance or contraindication to ribavirin.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old)
Peginterferon alpha-2b is indicated in a combination regimen with ribavirin for the treatment of children 3 years of age and older and adolescents, who have chronic hepatitis C, previously untreated, without liver decompensation, and who are positive for HCV-RNA.
When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The decision to treat should be made on a case by case basis.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Peginterferon alpha-2b is contraindicated in the following cases:
Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.